Lipid and Lipoprotein Metabolism in Human Health and Diseases—the 2nd Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 887

Special Issue Editor


E-Mail Website
Guest Editor
Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, 80131 Naples, Italy
Interests: familial hypercholesterolemia; cardiovascular disease lipoprotein; lipidomic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Collegues,

Lipids are essential components of cellular membranes and lipoproteins. Lipids play many essential roles in cellular functions, including cellular barriers, membrane matrices, signaling pathways and energy storage.

Lipid and lipoprotein metabolism represent a complex set of chemical reactions involving liver, bowel, and endothelial compartments. Specific proteins and enzymes are involved in this process and, when deficient, they cause human diseases (e.g., familial hypercholesterolemia (FH) or familial chylomicronemia syndrome (FCS)).

Since the 1950s, lipids have been extracted from cells or tissues and total lipid extracts have been analyzed by chromatography and mass spectrometry. Over the years, the detailed study of lipid and lipoprotein metabolism has led to greater knowledge of the pathophysiological mechanisms of dyslipidemias. Furthermore, the identification of new therapeutic targets has allowed for the treatment of pathologies that had been ignored until a few years ago (e.g., PCSK9, ANGPTL-3, ApoCIII and MTP inhibition).

New perspectives are emerging from novel laboratory approaches, in particular omics studies. The results of these studies are promising in identifying novel biomarkers that will help in the diagnosis, prognosis and treatment of human diseases (e.g., cancer and atherosclerotic vascular diseases). Moreover, a promising application is the characterization of endpoints in clinical trials, which remains a major issue in drug development.

The aim of the Special Issue is to give an update on new evidence in studies on lipid metabolism and multi-omics evaluations and to clarify the molecular features of human disease, particularly in hereditary lipid disorders. The present Special Issue is addressed towards basic and clinical research.  Reviews and original research articles are welcome. The topics included in the Special Issue are the following:

  • The role of lipids in various physiological processes and pathophysiological mechanisms of human disease;
  • The evaluation of lipidome modifications following pharmacological intervention;
  • Novel laboratory approaches (multi-omics) to human disease, in particular lipid disorders and atherosclerosis.

Dr. Ilenia Calcaterra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipoprotein
  • lipid metabolism
  • lipidome
  • lipidomics
  • mass spectrometry
  • hereditary lipid disorders
  • familial hypercholesterolemia
  • omic
  • metabolomic
  • genomic

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 806 KiB  
Article
Assessment of Platelet Aggregation and Thrombin Generation in Patients with Familial Chylomicronemia Syndrome Treated with Volanesorsen: A Cross-Sectional Study
by Ilenia Lorenza Calcaterra, Renata Santoro, Nicoletta Vitelli, Ferdinando Cirillo, Guido D’Errico, Cornelia Guerrino, Giovanna Cardiero, Maria Donata Di Taranto, Giuliana Fortunato, Gabriella Iannuzzo and Matteo Nicola Dario Di Minno
Biomedicines 2024, 12(9), 2017; https://doi.org/10.3390/biomedicines12092017 - 4 Sep 2024
Viewed by 440
Abstract
Background: The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat Familial Chylomicronemia Syndrome (FCS). Cases of decreased platelet count are reported among patients treated with volanesorsen. The aim of the study was to evaluate platelet function and thrombin generation (TG) [...] Read more.
Background: The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat Familial Chylomicronemia Syndrome (FCS). Cases of decreased platelet count are reported among patients treated with volanesorsen. The aim of the study was to evaluate platelet function and thrombin generation (TG) assessment in FCS patients receiving volanesorsen. We performed a cross-sectional study on FCS patients treated with volanesorsen. Methods: Changes in platelet count PLC were assessed from baseline to Tw12 and Tw36. To assess TG, samples were processed by CAT (with PPP-reagent LOW). The results were expressed by the thrombogram graphic (thrombin variation over time); LagTime; endogenous thrombin potential (ETP); peak; time to reach peak (ttpeak), StartTail and Velocity Index. Platelet aggregation was assessed by testing different agonists using the turbidimetry method. Results: Four FCS patients and four matched healthy controls were included in the present study. Changes in PLC were 30% at Tw12 and 34% at Tw36. Thrombin generation results showed values in the normal range (for patients and controls, respectively, LagTime:10.42 ± 4.40 and 9.25 ± 0.99; ttPeak:14.33 ± 4.01 and 13.10 ± 0.67; StartTail: 32.13 ± 3.54 and 29.46 ± 1.69; Velocity Index: 20.21 ± 3.63 and 33.05 ± 13.21; ETP: 599.80 ± 73.47 and 900.2 ± 210.99; peak value: 76.84 ± 1.07 and 123.30 ± 39.45) and no significant difference between cases and controls. Platelet aggregation test showed values in range, with no significant difference compared to healthy controls. Conclusions: Our study showed for the first time that no significant changes in general hemostasis assessed by TG and in platelet function were observed in FCS patients receiving volanesorsen. Full article
Show Figures

Figure 1

Back to TopTop